U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. Inspections, Compliance, Enforcement, and Criminal Investigations
  3. Compliance Actions and Activities
  4. Warning Letters
  5. Hospira Inc - 506761 - 06/27/2018
  1. Warning Letters

CLOSEOUT LETTER

Hospira Inc MARCS-CMS 506761 —

Recipient:
Hospira Inc

United States

Issuing Office:

United States

 

   

Black HHS-Blue FDA Logo

 

 
 
Division of Pharmaceutical Quality Operations III
300 River Place, Suite 5900
Detroit, MI 48207
Telephone: (313) 393-8100
Fax: (313) 393-8139 

June 27, 2018

UPS NEXT DAY
SIGNATURE REQUIRED

Mr. Ian C. Reed
Chairman and CEO
Pfizer Inc.
235 East 42nd St.
New York, NY 10017

Dear Mr. Reed:

The U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Hospira Inc., a Pfizer Company at 1776 Centennial Drive, McPherson, Kansas, from October 16-27, 2017.

The Food and Drug Administration has completed an evaluation of your firm’s corrective actions in response to our Warning Letter (Case 506761). Any continued concerns regarding your Warning Letter response will be addressed in additional correspondence. Based on our current evaluation, it appears that you have addressed the violations contained in this Warning Letter. Future FDA inspections and regulatory activities will further assess the adequacy and sustainability of these corrections.

This letter does not relieve you or your firm from the responsibility of taking all necessary steps to assure sustained compliance with the Federal Food, Drug, and Cosmetic Act and its implementing regulations or with other relevant legal authority. The Agency expects you and your firm to maintain compliance and will continue to monitor your state of compliance. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means.

Sincerely,
/S/

Nicholas F. Lyons
Director Compliance Branch
Division of Pharmaceutical Quality Operations Division III

cc:

Mr. Jonathan J. Rushford
Vice President Operations/Site Head
1776 Centennial Dr.
McPherson, KS 67460 

Back to Top